Study Progression on Non-small Cell Lung Cancer with EGFR Mutation 
Treated by Immune Checkpoint Inhibitors

In recent years, epidermal growth factor receptor tyrosine kinase inhibitors have been recommended by many guidelines as first-line drugs for advanced non-small cell lung cancer (NSCLC) with EGFR gene mutations and no resistance. However, with the prolongation of medication time, most appear acquire...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Rilan BAI, Naifei CHEN, Jiuwei CUI
פורמט: Artigo
שפה:Chinês
יצא לאור: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2018-08-01
סדרה:Chinese Journal of Lung Cancer
נושאים:
Immune checkpoint inhibitors
Lung neoplasms
EGFR mutation
PD-L1
גישה מקוונת:http://dx.doi.org/10.3779/j.issn.1009-3419.2018.08.11
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים